Control group
( DrugBank: - / KEGG DRUG: - )
4 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 84 |
| 13 | 多発性硬化症／視神経脊髄炎 | 657 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
Showing 1 to 10 of 84 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200058224 | 2022-05-0120220501 | 2022-04-0320220403 | The treatment of primidone for bulbar dysfunction in amyotrophic lateral sclerosis: A randomized, double-blind, cross-over controlled clinical trial The treatment of primidone for bulbar dysfunction in amyotrophic lateral sclerosis: A randomized, do ... | The treatment of primidone for bulbar dysfunction in amyotrophic lateral sclerosis: A randomized, double-blind, cross-over controlled clinical trial The treatment of primidone for bulbar dysfunction in amyotrophic lateral sclerosis: A randomized, do ... | amyotrophic lateral sclerosis | Group A:phase I: primidone 60 mg/d; Wash-out period: no intervention; phase II: placebo control;Group B:phase I: placebo control; Wash-out period: no intervention; phase II: primidone 60 mg/d; GroupA:phase I: primidone 60 mg/d; Wash-out period: no intervention; phase II: placebo control;Group ... | The First People's Hospital of Yichang | NULL | Pending | 18 | Both | Group A:50;Group B:50; | Phase 2 | China | |
| 2 | EUCTR2019-001862-13-PT (EUCTR) | 18/02/202220220218 | 21/05/202020200521 | Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS) | A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 s ... | patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classific ... | Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive ... | ABScience | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 495 | Phase 3 | United States;Portugal;Slovenia;Greece;Spain;Ireland;Israel;Russian Federation;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Norway;Germany;Netherlands;Sweden United States;Portugal;Slovenia;Greece;Spain;Ireland;Israel;Russian Federation;United Kingdom;Italy; ... | ||
| 3 | EUCTR2019-001862-13-GR (EUCTR) | 03/02/202220220203 | 26/11/202120211126 | Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS) | A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - Amyotrophic Lateral Sclerosis (ALS) A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 s ... | patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classific ... | Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive ... | AB Science | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 495 | Phase 3 | United States;Portugal;Slovenia;Greece;Spain;Ukraine;Ireland;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Norway;Germany;Netherlands;Sweden United States;Portugal;Slovenia;Greece;Spain;Ukraine;Ireland;Austria;Russian Federation;Israel;Unite ... | ||
| 4 | ChiCTR2100051913 | 2021-12-3120211231 | 2021-10-0920211009 | Sodium Phenylbutyrate Granules Combined with Tauroursodeoxycholic Acid Capsules for Amyotrophic Lateral Sclerosis: A Multicentre, Randomised, Double-blind, Placebo-controlled Clinical Trial Sodium Phenylbutyrate Granules Combined with Tauroursodeoxycholic Acid Capsules for Amyotrophic Late ... | Sodium Phenylbutyrate Granules Combined with Tauroursodeoxycholic Acid Capsules for Amyotrophic Lateral Sclerosis: A Multicentre, Randomised, Double-blind, Placebo-controlled Clinical Trial Sodium Phenylbutyrate Granules Combined with Tauroursodeoxycholic Acid Capsules for Amyotrophic Late ... | Amyotrophic lateral sclerosis | Experimental group:Sodium phenylbutyrate granules + tauroursodeoxycholic acid capsules;Control group:Sodium phenylbutyrate placebo + tauroursodeoxycholic acid placebo; Experimental group:Sodium phenylbutyrate granules + tauroursodeoxycholic acid capsules;Control group ... | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | NULL | Pending | 18 | 80 | Both | Experimental group:136;Control group:68; | N/A | China |
| 5 | EUCTR2019-001862-13-DK (EUCTR) | 21/09/202120210921 | 30/06/202020200630 | Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS) | A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 s ... | patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classific ... | Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive ... | AB Science | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 495 | Phase 3 | United States;Portugal;Slovenia;Spain;Ukraine;Ireland;Israel;Russian Federation;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Norway;Sweden United States;Portugal;Slovenia;Spain;Ukraine;Ireland;Israel;Russian Federation;United Kingdom;Italy ... | ||
| 6 | ChiCTR2100044085 | 2021-03-0120210301 | 2021-03-0920210309 | A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS). A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluat ... | A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS). A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluat ... | Amyotrophic lateral sclerosis | experimental group:Huoling Shengji Keli granules 1 bag + riluzole tablets simulant 1 tablet each time, Bid, oral;control group:Huoling Shengji Keli granules simulant 1 bag + riluzole tablets 1 tablet each time, Bid, oral; experimental group:Huoling Shengji Keli granules 1 bag + riluzole tablets simulant 1 tablet each tim ... | Peking University Third Hospital | NULL | Recruiting | 45 | 70 | Both | experimental group:72;control group:72; | Phase 2 | China |
| 7 | ITMCTR2100004558 | 2021-03-0120210301 | 2021-03-0920210309 | A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS). A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluat ... | A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS). A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluat ... | Amyotrophic lateral sclerosis | experimental group:Huoling Shengji Keli granules 1 bag + riluzole tablets simulant 1 tablet each time, Bid, oral;control group:Huoling Shengji Keli granules simulant 1 bag + riluzole tablets 1 tablet each time, Bid, oral; experimental group:Huoling Shengji Keli granules 1 bag + riluzole tablets simulant 1 tablet each tim ... | Peking University Third Hospital | NULL | Recruiting | 45 | 70 | Both | experimental group:72;control group:72; | Phase 2 | China |
| 8 | EUCTR2019-001862-13-IT (EUCTR) | 03/02/202120210203 | 06/11/202020201106 | Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS) | A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - non applicable A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 s ... | Patients suffering from Amyotrophic Lateral Sclerosis (ALS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Patients suffering from Amyotrophic Lateral Sclerosis (ALS);Therapeutic area: Diseases [C] - Nervous ... | Product Name: Masitinib mesilate Product Code: [AB1010] INN or Proposed INN: Masitinib mesilate Other descriptive name: 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base; AB 1003 Product Name: Masitinib mesilate Product Code: [AB1010] INN or Proposed INN: Masitinib mesilate Other descriptive name: 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base; AB 1003 Product Name: Masitinib mesilate Product Code: [AB1010] INN or Proposed INN: Masitinib mesilate Other d ... | AB SCIENCE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 495 | Phase 3 | United States;Portugal;Slovenia;Spain;Ukraine;Ireland;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Argentina;Belgium;Poland;Denmark;Norway;Germany;Netherlands;Sweden United States;Portugal;Slovenia;Spain;Ukraine;Ireland;Austria;Russian Federation;Israel;United Kingd ... | ||
| 9 | EUCTR2019-001862-13-NO (EUCTR) | 03/02/202120210203 | 20/11/202020201120 | Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS) | A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - not applicable A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 s ... | patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] patients suffering from Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classific ... | Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive name: na Product Name: masitinib Product Code: AB1010 INN or Proposed INN: Masitinib mesylate Other descriptive ... | ABScience | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 495 | Phase 3 | Portugal;United States;Slovenia;Spain;Ukraine;Ireland;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Canada;Argentina;Poland;Belgium;Denmark;Netherlands;Norway;Germany;Sweden Portugal;United States;Slovenia;Spain;Ukraine;Ireland;Austria;Israel;Russian Federation;United Kingd ... | ||
| 10 | ChiCTR2000028960 | 2021-01-0120210101 | 2020-01-0920200109 | Exploratory study of low-intensity ultrasound in the disease progression of amyotrophic lateral sclerosis Exploratory study of low-intensity ultrasound in the disease progression of amyotrophic lateral scle ... | Exploratory study of low-intensity ultrasound in the disease progression of amyotrophic lateral sclerosis Exploratory study of low-intensity ultrasound in the disease progression of amyotrophic lateral scle ... | Amyotrophic lateral sclerosis | experimental group:wearable low-intensity ultrasound and Riluzole;control group:ineffective ultrasound and Riluzole; experimental group:wearable low-intensity ultrasound and Riluzole;control group:ineffective ultrasou ... | University Affiliated Sixth People's Hospital | NULL | Pending | 18 | 70 | Both | experimental group:20;control group:20; | China |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
Showing 1 to 10 of 657 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05179577 (ClinicalTrials.gov) | June 202320230600 | 12/11/202120211112 | A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multip ... | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006) A Randomized, Double-Blind, Placebo-Controlled Parallel GroupStudy to Investigate the Safety and Eff ... | Spasticity | Drug: Arbaclofen;Drug: Placebo | RVL Pharmaceuticals, Inc. | NULL | Not yet recruiting | 18 Years | 65 Years | All | 442 | Phase 3 | NULL |
| 2 | NCT05754593 (ClinicalTrials.gov) | April 202320230400 | 21/2/202320230221 | Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Gro ... | Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis, Compared to a Control Group | Multiple Sclerosis | Biological: Anti-Mullerian hormone (AMH) level;Other: Antral follicle count (AFC);Other: Clinical assessment Biological: Anti-Mullerian hormone (AMH) level;Other: Antral follicle count (AFC);Other: Clinical as ... | University Hospital, Bordeaux | NULL | Not yet recruiting | 25 Years | 35 Years | Female | 160 | N/A | France |
| 3 | NCT05532943 (ClinicalTrials.gov) | December 31, 202220221231 | 5/9/202220220905 | Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients Wit ... | A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Co ... | Multiple Sclerosis | Biological: Allogeneic umbilical cord mesenchymal stem cells;Biological: Control group | Ever Supreme Bio Technology Co., Ltd. | NULL | Not yet recruiting | 20 Years | 65 Years | All | 41 | Phase 1/Phase 2 | Taiwan |
| 4 | ChiCTR2200057880 | 2022-04-0120220401 | 2022-03-2020220320 | A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG pos ... | A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG pos ... | Neuromyelitis optica spectrum disorder | Case group:Orelabrutinib, orally, 50 mg QD; | Peking Union Medical College Hospital | NULL | Pending | 18 | 75 | Both | Case group:23; | Phase 1 | China |
| 5 | NCT04990219 (ClinicalTrials.gov) | September 27, 202120210927 | 29/7/202120210729 | A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis | Interventional, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1B Study Investigating the Effects of Lu AG06466 for the Treatment of Spasticity in Patients With Multiple Sclerosis Interventional, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1B Study Investi ... | Multiple Sclerosis | Drug: Lu AG06466;Drug: Placebo | H. Lundbeck A/S | NULL | Terminated | 18 Years | 70 Years | All | 37 | Phase 1 | United States;Germany |
| 6 | NCT04079088 (ClinicalTrials.gov) | June 30, 202120210630 | 3/9/201920190903 | Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) or Glatiramer Acetate in Relapsing ... | A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evalu ... | Relapsing Multiple Sclerosis | Drug: Placebo;Drug: BIIB061;Biological: Interferon-beta1;Drug: Glatiramer acetate | Biogen | NULL | Not yet recruiting | 18 Years | 55 Years | All | 300 | Phase 2 | NULL |
| 7 | EUCTR2019-004980-36-RO (EUCTR) | 29/06/202120210629 | 27/04/202220220427 | Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. - Phase III Study of Evobrutinib in RMS (EVOLUTION RMS 2) A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ... | Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ... | Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: MSC2364447C Trade Name: Aubagio Product Name: Aubagio INN or Proposed INN: TERIFLUNOMIDE Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ... | Merck Healthcare KGaA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 930 | Phase 3 | Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russian Federation;Switzerland;Italy;India;France;Puerto Rico;Malaysia;South Africa;Kuwait;Tunisia;Latvia;Moldova, Republic of;Slovenia;Lithuania;Turkey;Mexico;Canada;Poland;Brazil;Singapore;Romania;Bulgaria;Norway;Germany;Sweden Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russi ... | ||
| 8 | EUCTR2019-004980-36-SI (EUCTR) | 18/03/202120210318 | 06/10/202020201006 | Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. - Phase III Study of Evobrutinib in RMS (EVOLUTION RMS 2) A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ... | Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ... | Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: MSC2364447C Trade Name: Aubagio Product Name: Aubagio INN or Proposed INN: TERIFLUNOMIDE Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ... | Merck Healthcare KGaA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 930 | Phase 3 | Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russian Federation;Switzerland;Italy;India;France;Puerto Rico;Malaysia;South Africa;Latvia;Kuwait;Tunisia;Moldova, Republic of;Slovenia;Lithuania;Turkey;Mexico;Canada;Poland;Brazil;Singapore;Romania;Bulgaria;Norway;Germany;Sweden Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russi ... | ||
| 9 | EUCTR2019-004980-36-NO (EUCTR) | 16/12/202020201216 | 03/07/202020200703 | Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety. - Phase III Study of Evobrutinib in RMS (EVOLUTION RMS 2) A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled ... | Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ... | Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: MSC2364447C Trade Name: Aubagio Product Name: Aubagio INN or Proposed INN: TERIFLUNOMIDE Product Name: Evobrutinib Product Code: M2951 INN or Proposed INN: EVOBRUTINIB Other descriptive name: ... | Merck Healthcare KGaA | NULL | Not Recruiting | Female: yes Male: yes | 930 | Phase 3 | Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russian Federation;Switzerland;Italy;India;France;Puerto Rico;Malaysia;South Africa;Kuwait;Tunisia;Latvia;Moldova, Republic of;Slovenia;Lithuania;Turkey;Mexico;Canada;Poland;Brazil;Singapore;Romania;Bulgaria;Norway;Germany;Sweden Portugal;Belarus;United States;Philippines;Saudi Arabia;Slovakia;Greece;Spain;Thailand;Ukraine;Russi ... | ||
| 10 | EUCTR2019-001967-58-FR (EUCTR) | 20/11/202020201120 | 27/05/202020200527 | Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with Relapsing Multiple Sclerosis (RMS) Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with Relapsing Multiple S ... | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis - Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Paralle ... | Relapsing Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Relapsing Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relap ... | Product Name: Dapirolizumab Pegol Product Code: BIIB133 INN or Proposed INN: DAPIROLIZUMAB PEGOL Trade Name: Ocrevus Product Name: OCREVUS INN or Proposed INN: OCRELIZUMAB Other descriptive name: OCRELIZUMAB Product Name: Dapirolizumab Pegol Product Code: BIIB133 INN or Proposed INN: DAPIROLIZUMAB PEGOL Trade ... | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 220 | Phase 2 | United States;Serbia;France;Spain;Poland;Belgium;Germany;Switzerland;Italy |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
Showing 1 to 10 of 568 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2200006853 | 2022-12-1420221214 | 2022-12-0620221206 | Clinical study on the treatment of advanced rheumatoid arthritis (Phlegm stasis bi syndrome) by Soufeng Sanjie fomula for inhibiting bone erosion Clinical study on the treatment of advanced rheumatoid arthritis (Phlegm stasis bi syndrome) by Souf ... | medicine | Rheumatoid arthritis | control group:MTX;Observation group:MTX+Traditional Chinese medicine (TCM); | Jiangsu Integrated Traditional Chinese and Western Medicine Hospital | NULL | Recruiting | 18 | 70 | Both | control group:30;Observation group:30; | China | |
| 2 | ITMCTR2200006093 | 2022-06-0120220601 | 2022-06-1120220611 | Evaluation of clinical efficacy of Lv's 'Shu Jin San' in the treatment of rheumatoid arthritis with cold-dampness syndrome Evaluation of clinical efficacy of Lv's 'Shu Jin San' in the treatment of rheumatoid arthritis with ... | Evaluation of clinical efficacy of Lv's 'Shu Jin San' in the treatment of rheumatoid arthritis with cold-dampness syndrome Evaluation of clinical efficacy of Lv's 'Shu Jin San' in the treatment of rheumatoid arthritis with ... | Rheumatoid Arthritis | therapy group:MTX 10mg po qw + Lv's Shu Jin San 15g po qd;control group:MTX 10mg po qw; | Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine | NULL | Recruiting | 18 | 75 | Both | therapy group:18;control group:18; | China | |
| 3 | NCT05380934 (ClinicalTrials.gov) | May 202220220500 | 16/5/202220220516 | A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects | A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of TQH3821 in Adult Healthy Subjects A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of TQH3821 in Adult Healthy Su ... | Rheumatoid Arthritis | Drug: TQH3821 tablets;Drug: TQH3821 tablets (Placebo);Drug: Methotrexate tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NULL | Recruiting | 18 Years | 55 Years | All | 62 | Phase 1 | China |
| 4 | NCT04688398 (ClinicalTrials.gov) | January 20, 202220220120 | 14/12/202020201214 | Study of the Impact of Fatty Acids From Seal Oil on the Relief of Symptoms Associated With Rheumatoid Arthritis Study of the Impact of Fatty Acids From Seal Oil on the Relief of Symptoms Associated With Rheumatoi ... | Study of the Impact of Fatty Acids From Seal Oil on the Relief of Symptoms Associated With Rheumatoid Arthritis Study of the Impact of Fatty Acids From Seal Oil on the Relief of Symptoms Associated With Rheumatoi ... | Polyarthritis | Dietary Supplement: Seal oil;Dietary Supplement: Control | Laval University | Ministry of Agriculture, Fisheries and Food, Quebec;Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc. Ministry of Agriculture, Fisheries and Food, Quebec;Groupe De Recherche En Rhumatologie Et Maladies ... | Recruiting | 18 Years | N/A | All | 130 | N/A | Canada |
| 5 | ChiCTR2100053999 | 2021-12-0120211201 | 2021-12-0620211206 | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLi ... | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLi ... | Rheumatism | Experimental group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acid tablets;Control group:methotrexate + folic acid tablets; Experimental group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acid tablets;Co ... | Yunnan Hospital of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | Experimental group:36;Control group:36; | China | |
| 6 | ChiCTR2100054305 | 2021-12-0120211201 | 2021-12-1320211213 | Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixed syndrome of cold and heat Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixe ... | Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixed syndrome of cold and heat Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixe ... | Rheumatoid Arthritis | Treatment group:Modified Qianyang Fengsui Dan + Methotrexate Tablets + Folic Acid Tablets;Control group:Methotrexate + Folic Acid; Treatment group:Modified Qianyang Fengsui Dan + Methotrexate Tablets + Folic Acid Tablets;Control gr ... | Yunnan Provincial Hospital of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | Treatment group:36;Control group:36; | China | |
| 7 | ITMCTR2100005379 | 2021-12-0120211201 | 2021-12-0620211206 | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLi ... | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLi ... | Rheumatism | The treatment group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acid tablets;The control group:methotrexate + folic acid tablets; The treatment group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acid tablets;T ... | Yunnan Hospital of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | The treatment group:36;The control group:36; | China | |
| 8 | NCT04991753 (ClinicalTrials.gov) | October 14, 202120211014 | 2/8/202120210802 | A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheum ... | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants With Active Rheumatoid Arthritis Despite Standard Therapy A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study ... | Arthritis, Rheumatoid | Other: Placebo;Drug: Nipocalimab | Janssen Research & Development, LLC | NULL | Completed | 18 Years | 75 Years | All | 53 | Phase 2 | United States;Germany;Poland;Spain;United Kingdom |
| 9 | EUCTR2021-000510-42-DE (EUCTR) | 05/10/202120211005 | 16/07/202120210716 | A Proof-of-concept Study of the Efficacy and Safety of Nipocalimabin Participants with Active Rheumatoid Arthritis. A Proof-of-concept Study of the Efficacy and Safety of Nipocalimabin Participants with Active Rheuma ... | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants with Active Rheumatoid Arthritis Despite Standard Therapy. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study ... | Rheumatoid Arthritis (RA) MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Rheumatoid Arthritis (RA) MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumato ... | Product Name: Nipocalimab Product Code: JNJ-80202135 INN or Proposed INN: Nipocalimab Other descriptive name: M281 Product Name: Nipocalimab Product Code: JNJ-80202135 INN or Proposed INN: Nipocalimab Other descriptive ... | Janssen-Cilag International NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | United States;Spain;Poland;Germany;United Kingdom | ||
| 10 | ChiCTR2100048769 | 2021-09-2920210929 | 2021-07-1620210716 | Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of Qufengzhitong capsule in the treatment of rheumatoid arthritis Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of Qufengzhito ... | Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of Qufengzhitong capsule in the treatment of rheumatoid arthritis Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of Qufengzhito ... | rheumatoid arthritis | Test group:Methotrexate tablets+Qufengzhitong capsule;control group:Methotrexate tablets+Qufeng Zhitong Capsule Placebo; Test group:Methotrexate tablets+Qufengzhitong capsule;control group:Methotrexate tablets+Qufeng Zhit ... | Guang'anmen Hospital, China Academy of Chinese Medical Sciences | NULL | Pending | 18 | 75 | Both | Test group:102;control group:102; | Phase 4 | china |
70. 広範脊柱管狭窄症
臨床試験数 : 95 / 薬物数 : 169 - (DrugBank : 61) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 90
Showing 1 to 9 of 9 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100053054 | 2021-11-0920211109 | 2021-11-1020211110 | Desomumab and lumbar spinal stenosis | Evaluation of bone mineral density and function at 1 year after lumbar spinal stenosis and fusion with desomumab: a parallel double-blind randomized controlled clinical trial Evaluation of bone mineral density and function at 1 year after lumbar spinal stenosis and fusion wi ... | Lumber disease | Group A:Denosumab;Group B:Placebo; | The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Techn ... | NULL | Recruiting | 40 | 90 | Both | Group A:40;Group B:40; | Phase 4 | China |
| 2 | ChiCTR2100046515 | 2021-06-0120210601 | 2021-05-1820210518 | To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spinal Stenosis Based on the Theory of 'Yanghua Qi' To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spin ... | To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spinal Stenosis Based on the Theory of 'Yanghua Qi' To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spin ... | Degenerative lumbar spinal stenosis | Treatment group:Zhuanyaotang Decoction granules + Mecobalamin tablets simulation agent+ Celecoxib capsules simulation agent;Control group:Methobalamin tablet + Celecoxib capsule + Zhuanyaotang Decoction granule simulation agent; Treatment group:Zhuanyaotang Decoction granules + Mecobalamin tablets simulation agent+ Celecoxib ca ... | Wang Jing Hospital, Chinese Academy of Traditional Chinese Medicine | NULL | Recruiting | 45 | 70 | Both | Treatment group:52;Control group:52; | N/A | China |
| 3 | ITMCTR2100004862 | 2021-06-0120210601 | 2021-05-1820210518 | To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spinal Stenosis Based on the Theory of 'Yanghua Qi' To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spin ... | To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spinal Stenosis Based on the Theory of 'Yanghua Qi' To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spin ... | Degenerative lumbar spinal stenosis | Control group:Methobalamin tablet + Celecoxib capsule + Zhuanyaotang Decoction granule simulation agent;Treatment group:Zhuanyaotang Decoction granules + Mecobalamin tablets simulation agent+ Celecoxib capsules simulation agent; Control group:Methobalamin tablet + Celecoxib capsule + Zhuanyaotang Decoction granule simulation ag ... | Wang Jing Hospital, Chinese Academy of Traditional Chinese Medicine | NULL | Recruiting | 45 | 70 | Both | Control group:52;Treatment group:52; | N/A | China |
| 4 | JPRN-UMIN000030881 | 2018/01/1820180118 | 18/01/201820180118 | Dietary supplementation in patients following lumbar spine surgery: a randomized controlled trial | Dietary supplementation in patients following lumbar spine surgery: a randomized controlled trial - Dietary supplementation in patients following lumbar spine surgery Dietary supplementation in patients following lumbar spine surgery: a randomized controlled trial - ... | lumbar spinal stenosis | Intervention group Twice-daily ingestion of amino acids supplementation for 3 weeks after spinal surgery (100kcal, protein 10g) Postoperative rehabilitation for 3 weeks Control group Twice-daily ingestion of placebo (non amino acids) supplementation for 3 weeks after spinal surgery (100kcal, protein 0g ) Postoperative rehabilitation for 3 weeks Intervention group Twice-daily ingestion of amino acids supplementation for 3 weeks after spinal surg ... | Wakayama Medical University | NULL | Complete: follow-up continuing | 50years-old | 90years-old | Male and Female | 80 | Not selected | Japan |
| 5 | ChiCTR-INR-17012403 | 2017-09-0120170901 | 2017-08-1720170817 | Application of erythropoietin in enriched bone marrow stem cells technique to promote bone regeneration Application of erythropoietin in enriched bone marrow stem cells technique to promote bone regenerat ... | Application of erythropoietin in enriched bone marrow stem cells technique to promote bone regeneration Application of erythropoietin in enriched bone marrow stem cells technique to promote bone regenerat ... | bone defect, bone non-union and lumber spinal stenosis | treatment group:administer erythropoietin (150U/kg) three to five times via subcutaneous or intravenous injection before operation;controlled group:administer normal saline three times via subcutaneous or intravenous injection before operation; treatment group:administer erythropoietin (150U/kg) three to five times via subcutaneous or intraven ... | Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine | NULL | Pending | 18 | 65 | Both | treatment group:44;controlled group:44; | China | |
| 6 | NCT02902380 (ClinicalTrials.gov) | September 27, 201620160927 | 6/9/201620160906 | The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in ... | Spinal Stenosis | Drug: dexmedetomidine group;Drug: control group | Yonsei University | NULL | Completed | 20 Years | 70 Years | All | 52 | N/A | Korea, Republic of | |
| 7 | EUCTR2015-002694-37-FI (EUCTR) | 01/09/201620160901 | 04/01/201620160104 | Dexmedetomidine is a drug that is used mainly for sedation in the intensive care unit. Purpose of this study is to determine does Dexmedetomidine infusion provide pain management in the postoperative period and prevent chronic pain. Patients are randomized to receive either placebo or dexmedetomidine infusion. DEXPAIN-study has been approved by Kuopio university hospitals ethics committee. Dexmedetomidine is a drug that is used mainly for sedation in the intensive care unit. Purpose of th ... | Dexmedetomidine infusion in pain management during low back surgeryDexmedetomidine is an alpha-2-adrenergic agonist that is used mainly for sedation in the intensive care unit. Alpha-2-adrenoceptors agonists have several beneficial actions in a surgical patient. They decrease symphatetic tone, reduce anesthetic and opioid requirements and cause sedation and analgesia. Pain after low back surgery is intense and can become chronic. We need a new drug to manage pain during postoperative period and to prevent chronic pain.DEXPAIN-study has been approved by Kuopio university hospitals ethics committee. Study is single centered, randomized and placebo-controlled study. A total of 60 patients scheduled for low back surgery will be enrolled in this study. Patients eligibility will be assessed by pre-determined inclusion-exclusion-criteria. Purpose of this study is to determine does Dexmedetomidine infusion provide pain management in the postoperative period and prevent chronic pain. Patients are randomized to receive either placebo or dexmedetomidine infusion. Patients in the dexmedetomidine group receive dexmedetomidine loading dose 1ug/kg for 10 minutes and continuous infusion 1.4 ug/kg/h during surgery and post-anesthesia care unit. Total infusion time will be four hours. Anesthesia is standardized and post-operative pain is treated with patient controlled analgesia made of oxycodone. Questionnaires will be used to assess pain control.Study is scheduled to start as soon as we obtain permission from Finnish Medicines Agency and receive sufficient funding. Dexmedetomidine infusion in pain management during low back surgeryDexmedetomidine is an alpha-2-adr ... | Low back pain, Discus prolapse, Spinal stenosis;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] Low back pain, Discus prolapse, Spinal stenosis;Therapeutic area: Analytical, Diagnostic and Therape ... | Trade Name: Dexmedetomidine Product Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE | Kuopio University hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | Finland | ||||
| 8 | ChiCTR-TRC-13003639 | 2012-09-1320120913 | 2013-09-0720130907 | The application of Analgesia Nociception Index guided Remifentanil administration during general anesthesia for Spinal Surgery The application of Analgesia Nociception Index guided Remifentanil administration during general ane ... | The application of Analgesia Nociception Index guided Remifentanil administration during general anesthesia for Spinal Surgery The application of Analgesia Nociception Index guided Remifentanil administration during general ane ... | Lumbar spinal stenosis and/or lumbar intervertebral disc herniation | ANI group:ANI guide the administration of remifentanil;control group:remifentanil was adapted by Anaesthesiologist corresponding to clinical experiences ; ANI group:ANI guide the administration of remifentanil;control group:remifentanil was adapted by Ana ... | Peking University Third Hospital | NULL | Completed | 18 | 70 | Both | ANI group:30;control group:30; | China | |
| 9 | NCT01456377 (ClinicalTrials.gov) | July 201120110700 | 12/10/201120111012 | The Effectiveness of Oral Corticosteroids in the Treatment of Lumbar Stenosis | A Prospective Controlled Study Randomized Double Blind Study, Evaluate the Effectiveness of Oral Corticosteroids in the Treatment of Stenosis of Lumbar Canal In Symptomatic Patients A Prospective Controlled Study Randomized Double Blind Study, Evaluate the Effectiveness of Oral Cor ... | Spinal Stenosis of Lumbar Region | Drug: predinose oral;Drug: placebo group | Federal University of São Paulo | NULL | Recruiting | 50 Years | 75 Years | Both | 60 | N/A | Brazil |